nodes	percent_of_prediction	percent_of_DWPC	metapath
Sibutramine—SLC6A3—Parkinson's disease	0.779	1	CbGaD
Sibutramine—SLC6A2—locus ceruleus—Parkinson's disease	0.0118	0.155	CbGeAlD
Sibutramine—SLC6A2—sympathetic nervous system—Parkinson's disease	0.00935	0.123	CbGeAlD
Sibutramine—SLC6A3—telencephalic ventricle—Parkinson's disease	0.00695	0.0912	CbGeAlD
Sibutramine—SLC6A2—autonomic nervous system—Parkinson's disease	0.00629	0.0825	CbGeAlD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—PITX3—Parkinson's disease	0.00568	0.0393	CbGpPWpGaD
Sibutramine—SLC6A3—Clearance of dopamine—COMT—Parkinson's disease	0.00461	0.0319	CbGpPWpGaD
Sibutramine—SLC6A3—Clearance of dopamine—MAOA—Parkinson's disease	0.00458	0.0317	CbGpPWpGaD
Sibutramine—SLC6A3—nerve—Parkinson's disease	0.00438	0.0575	CbGeAlD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—LMX1A—Parkinson's disease	0.0043	0.0298	CbGpPWpGaD
Sibutramine—SLC6A3—Alpha-synuclein signaling—SNCAIP—Parkinson's disease	0.00356	0.0246	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—PINK1—Parkinson's disease	0.00356	0.0246	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—SEPT5—Parkinson's disease	0.00356	0.0246	CbGpPWpGaD
Sibutramine—SLC6A2—nerve—Parkinson's disease	0.00354	0.0464	CbGeAlD
Sibutramine—SLC6A3—hindbrain—Parkinson's disease	0.00328	0.0431	CbGeAlD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—EN1—Parkinson's disease	0.00326	0.0225	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—SNCAIP—Parkinson's disease	0.00303	0.0209	CbGpPWpGaD
Sibutramine—SLC6A4—hindbrain—Parkinson's disease	0.00301	0.0395	CbGeAlD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—HTRA2—Parkinson's disease	0.0027	0.0187	CbGpPWpGaD
Sibutramine—SLC6A4—Monoamine Transport—DBH—Parkinson's disease	0.00262	0.0181	CbGpPWpGaD
Sibutramine—CYP3A4—Felbamate Metabolism—CYP2E1—Parkinson's disease	0.00236	0.0163	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—ATXN2—Parkinson's disease	0.00229	0.0159	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—DBH—Parkinson's disease	0.00225	0.0156	CbGpPWpGaD
Sibutramine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC18A2—Parkinson's disease	0.00213	0.0148	CbGpPWpGaD
Sibutramine—SLC6A4—Serotonin Transporter Activity—MAOA—Parkinson's disease	0.00213	0.0147	CbGpPWpGaD
Sibutramine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—COMT—Parkinson's disease	0.0021	0.0146	CbGpPWpGaD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—NR4A2—Parkinson's disease	0.0021	0.0145	CbGpPWpGaD
Sibutramine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—MAOA—Parkinson's disease	0.00209	0.0145	CbGpPWpGaD
Sibutramine—SLC6A3—Alpha-synuclein signaling—PARK7—Parkinson's disease	0.00205	0.0142	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—GPR37—Parkinson's disease	0.00204	0.0141	CbGpPWpGaD
Sibutramine—SLC6A3—Monoamine Transport—DBH—Parkinson's disease	0.00199	0.0138	CbGpPWpGaD
Sibutramine—SLC6A3—Na+/Cl- dependent neurotransmitter transporters—SLC18A2—Parkinson's disease	0.00189	0.0131	CbGpPWpGaD
Sibutramine—SLC6A3—brainstem—Parkinson's disease	0.00188	0.0247	CbGeAlD
Sibutramine—SLC6A3—Alpha-synuclein signaling—UCHL1—Parkinson's disease	0.00187	0.0129	CbGpPWpGaD
Sibutramine—SLC6A3—Alpha-synuclein signaling—GRK5—Parkinson's disease	0.00182	0.0126	CbGpPWpGaD
Sibutramine—SLC6A3—forebrain—Parkinson's disease	0.00182	0.0238	CbGeAlD
Sibutramine—SLC6A4—Synaptic Vesicle Pathway—PARK7—Parkinson's disease	0.0018	0.0125	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—PARK7—Parkinson's disease	0.00174	0.012	CbGpPWpGaD
Sibutramine—SLC6A4—brainstem—Parkinson's disease	0.00172	0.0226	CbGeAlD
Sibutramine—SLC6A4—forebrain—Parkinson's disease	0.00166	0.0218	CbGeAlD
Sibutramine—SLC6A3—Alpha-synuclein signaling—SNCA—Parkinson's disease	0.00164	0.0113	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—UCHL1—Parkinson's disease	0.00159	0.011	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—LRRK2—Parkinson's disease	0.00155	0.0107	CbGpPWpGaD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—DDC—Parkinson's disease	0.00154	0.0107	CbGpPWpGaD
Sibutramine—SLC6A2—brainstem—Parkinson's disease	0.00152	0.0199	CbGeAlD
Sibutramine—SLC6A2—Amine compound SLC transporters—SLC18A2—Parkinson's disease	0.00148	0.0102	CbGpPWpGaD
Sibutramine—SLC6A2—forebrain—Parkinson's disease	0.00146	0.0192	CbGeAlD
Sibutramine—SLC6A4—Monoamine Transport—ADORA2A—Parkinson's disease	0.00143	0.00992	CbGpPWpGaD
Sibutramine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Parkinson's disease	0.0014	0.00967	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—SNCA—Parkinson's disease	0.00139	0.00961	CbGpPWpGaD
Sibutramine—SLC6A3—Amine compound SLC transporters—SLC18A2—Parkinson's disease	0.00131	0.00907	CbGpPWpGaD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—SLC18A2—Parkinson's disease	0.00131	0.00907	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—DDC—Parkinson's disease	0.00128	0.00883	CbGpPWpGaD
Sibutramine—SLC6A3—Alpha-synuclein signaling—MAOB—Parkinson's disease	0.00126	0.00874	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—ADORA2A—Parkinson's disease	0.00123	0.00853	CbGpPWpGaD
Sibutramine—SLC6A3—midbrain—Parkinson's disease	0.0012	0.0157	CbGeAlD
Sibutramine—SLC6A3—spinal cord—Parkinson's disease	0.00117	0.0153	CbGeAlD
Sibutramine—SLC6A3—Alpha-synuclein signaling—PARK2—Parkinson's disease	0.00117	0.00806	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—EN1—Parkinson's disease	0.00114	0.00791	CbGpPWpGaD
Sibutramine—SLC6A4—Synaptic Vesicle Pathway—SLC18A2—Parkinson's disease	0.00113	0.00779	CbGpPWpGaD
Sibutramine—SLC6A4—midbrain—Parkinson's disease	0.0011	0.0144	CbGeAlD
Sibutramine—SLC6A3—Monoamine Transport—ADORA2A—Parkinson's disease	0.00109	0.00756	CbGpPWpGaD
Sibutramine—SLC6A4—spinal cord—Parkinson's disease	0.00107	0.0141	CbGeAlD
Sibutramine—SLC6A4—Monoamine Transport—SLC6A3—Parkinson's disease	0.00107	0.00741	CbGpPWpGaD
Sibutramine—SLC6A4—Monoamine Transport—TH—Parkinson's disease	0.00107	0.00741	CbGpPWpGaD
Sibutramine—SLC6A2—medulla oblongata—Parkinson's disease	0.00106	0.0139	CbGeAlD
Sibutramine—SLC6A3—head—Parkinson's disease	0.00104	0.0136	CbGeAlD
Sibutramine—SLC6A4—Serotonin Transporter Activity—IL1B—Parkinson's disease	0.00103	0.0071	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—PARK2—Parkinson's disease	0.00099	0.00685	CbGpPWpGaD
Sibutramine—SLC6A3—nervous system—Parkinson's disease	0.000986	0.0129	CbGeAlD
Sibutramine—SLC6A2—Amine compound SLC transporters—SLC6A3—Parkinson's disease	0.00097	0.00671	CbGpPWpGaD
Sibutramine—SLC6A4—head—Parkinson's disease	0.000953	0.0125	CbGeAlD
Sibutramine—SLC6A3—central nervous system—Parkinson's disease	0.000949	0.0124	CbGeAlD
Sibutramine—SLC6A3—cerebellum—Parkinson's disease	0.000928	0.0122	CbGeAlD
Sibutramine—SLC6A2—Monoamine Transport—TH—Parkinson's disease	0.000922	0.00637	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—SLC6A3—Parkinson's disease	0.000922	0.00637	CbGpPWpGaD
Sibutramine—SLC6A4—nervous system—Parkinson's disease	0.000903	0.0118	CbGeAlD
Sibutramine—SLC6A4—central nervous system—Parkinson's disease	0.00087	0.0114	CbGeAlD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—ATP1A3—Parkinson's disease	0.000867	0.006	CbGpPWpGaD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—TH—Parkinson's disease	0.00086	0.00595	CbGpPWpGaD
Sibutramine—CYP3A4—Codeine and Morphine Metabolism—CYP2D6—Parkinson's disease	0.00085	0.00588	CbGpPWpGaD
Sibutramine—SLC6A2—head—Parkinson's disease	0.000839	0.011	CbGeAlD
Sibutramine—SLC6A3—Alpha-synuclein signaling—TH—Parkinson's disease	0.000837	0.00579	CbGpPWpGaD
Sibutramine—SLC6A3—Monoamine Transport—TH—Parkinson's disease	0.000816	0.00565	CbGpPWpGaD
Sibutramine—SLC6A2—nervous system—Parkinson's disease	0.000795	0.0104	CbGeAlD
Sibutramine—SLC6A2—central nervous system—Parkinson's disease	0.000766	0.01	CbGeAlD
Sibutramine—SLC6A3—brain—Parkinson's disease	0.000753	0.00988	CbGeAlD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—TH—Parkinson's disease	0.000711	0.00492	CbGpPWpGaD
Sibutramine—SLC6A4—brain—Parkinson's disease	0.00069	0.00906	CbGeAlD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—CYCS—Parkinson's disease	0.000683	0.00473	CbGpPWpGaD
Sibutramine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—Parkinson's disease	0.000656	0.00454	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—HCN3—Parkinson's disease	0.000614	0.00425	CbGpPWpGaD
Sibutramine—SLC6A2—brain—Parkinson's disease	0.000608	0.00797	CbGeAlD
Sibutramine—CYP3A4—Codeine and Morphine Metabolism—ABCB1—Parkinson's disease	0.000607	0.0042	CbGpPWpGaD
Sibutramine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC18A2—Parkinson's disease	0.000579	0.004	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—DDC—Parkinson's disease	0.000541	0.00374	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—GSTA4—Parkinson's disease	0.000539	0.00373	CbGpPWpGaD
Sibutramine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—Parkinson's disease	0.000533	0.00368	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—KCNJ4—Parkinson's disease	0.000517	0.00357	CbGpPWpGaD
Sibutramine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC18A2—Parkinson's disease	0.000513	0.00355	CbGpPWpGaD
Sibutramine—CYP3A4—Fatty Acid Omega Oxidation—CYP2D6—Parkinson's disease	0.000488	0.00338	CbGpPWpGaD
Sibutramine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—Parkinson's disease	0.000472	0.00326	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—GSTA4—Parkinson's disease	0.000463	0.00321	CbGpPWpGaD
Sibutramine—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—Parkinson's disease	0.000447	0.00309	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—DLG1—Parkinson's disease	0.000446	0.00308	CbGpPWpGaD
Sibutramine—CYP3A4—nervous system—Parkinson's disease	0.000442	0.0058	CbGeAlD
Sibutramine—SLC6A4—Circadian rythm related genes—DDC—Parkinson's disease	0.000442	0.00306	CbGpPWpGaD
Sibutramine—SLC6A4—Monoamine Transport—IL1B—Parkinson's disease	0.000437	0.00302	CbGpPWpGaD
Sibutramine—CYP3A4—central nervous system—Parkinson's disease	0.000426	0.00559	CbGeAlD
Sibutramine—SLC6A3—NRF2 pathway—GSTA4—Parkinson's disease	0.000411	0.00284	CbGpPWpGaD
Sibutramine—CYP3A4—Xenobiotics—CYP2D6—Parkinson's disease	0.000409	0.00283	CbGpPWpGaD
Sibutramine—CYP3A4—Estrogen metabolism—NQO1—Parkinson's disease	0.000402	0.00278	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—KCNJ4—Parkinson's disease	0.000396	0.00274	CbGpPWpGaD
Sibutramine—CYP3A4—Tamoxifen metabolism—CYP2D6—Parkinson's disease	0.000393	0.00272	CbGpPWpGaD
Sibutramine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Parkinson's disease	0.000379	0.00262	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—IL1B—Parkinson's disease	0.000376	0.0026	CbGpPWpGaD
Sibutramine—CYP3A4—Xenobiotics—CYP2E1—Parkinson's disease	0.000374	0.00258	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CHRNA4—Parkinson's disease	0.000364	0.00252	CbGpPWpGaD
Sibutramine—CYP3A4—Tamoxifen metabolism—CYP2E1—Parkinson's disease	0.000359	0.00249	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—HTR1A—Parkinson's disease	0.000351	0.00242	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—GRIK1—Parkinson's disease	0.000349	0.00241	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—TAC1—Parkinson's disease	0.000345	0.00239	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—DLG1—Parkinson's disease	0.000342	0.00236	CbGpPWpGaD
Sibutramine—CYP3A4—Estrogen metabolism—COMT—Parkinson's disease	0.000337	0.00233	CbGpPWpGaD
Sibutramine—CYP3A4—Tryptophan metabolism—DDC—Parkinson's disease	0.000335	0.00232	CbGpPWpGaD
Sibutramine—SLC6A3—Monoamine Transport—IL1B—Parkinson's disease	0.000333	0.0023	CbGpPWpGaD
Sibutramine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—Parkinson's disease	0.000332	0.0023	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—ADORA2A—Parkinson's disease	0.00033	0.00228	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—NQO1—Parkinson's disease	0.000323	0.00223	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—HSPA1A—Parkinson's disease	0.00032	0.00222	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—SLC6A3—Parkinson's disease	0.000318	0.0022	CbGpPWpGaD
Sibutramine—SLC6A4—Monoamine Transport—TNF—Parkinson's disease	0.000317	0.00219	CbGpPWpGaD
Sibutramine—CYP3A4—Estrogen metabolism—GSTM1—Parkinson's disease	0.000308	0.00213	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—TH—Parkinson's disease	0.000302	0.00209	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—GRIK2—Parkinson's disease	0.000297	0.00205	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—CASP3—Parkinson's disease	0.00029	0.002	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—SLC18A2—Parkinson's disease	0.000287	0.00199	CbGpPWpGaD
Sibutramine—CYP3A4—Tryptophan metabolism—MAOB—Parkinson's disease	0.000282	0.00195	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—NQO1—Parkinson's disease	0.000278	0.00192	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—DRD1—Parkinson's disease	0.000276	0.00191	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—HSPA1A—Parkinson's disease	0.000276	0.00191	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—SLC6A3—Parkinson's disease	0.000274	0.00189	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—TNF—Parkinson's disease	0.000273	0.00189	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—GSTP1—Parkinson's disease	0.000269	0.00186	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—DRD3—Parkinson's disease	0.000268	0.00185	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GRIK1—Parkinson's disease	0.000267	0.00185	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—HMOX1—Parkinson's disease	0.000266	0.00184	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC18A2—Parkinson's disease	0.000263	0.00182	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—MAOA—Parkinson's disease	0.000255	0.00176	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ATP1A3—Parkinson's disease	0.000252	0.00174	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—TRPM7—Parkinson's disease	0.000252	0.00174	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—GSTM1—Parkinson's disease	0.000247	0.00171	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—HGF—Parkinson's disease	0.000247	0.00171	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—TH—Parkinson's disease	0.000246	0.0017	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—NQO1—Parkinson's disease	0.000246	0.0017	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—BDNF—Parkinson's disease	0.000246	0.0017	CbGpPWpGaD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—Parkinson's disease	0.000244	0.00169	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—HSPA1A—Parkinson's disease	0.000244	0.00169	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—DRD2—Parkinson's disease	0.000242	0.00167	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—HTR7—Parkinson's disease	0.000242	0.00167	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—CP—Parkinson's disease	0.000242	0.00167	CbGpPWpGaD
Sibutramine—SLC6A3—Monoamine Transport—TNF—Parkinson's disease	0.000242	0.00167	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC18A2—Parkinson's disease	0.000233	0.00161	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—GSTP1—Parkinson's disease	0.000232	0.0016	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—HMOX1—Parkinson's disease	0.000228	0.00158	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—CHRNA4—Parkinson's disease	0.000227	0.00157	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GRIK2—Parkinson's disease	0.000227	0.00157	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—TRPM7—Parkinson's disease	0.000223	0.00154	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ATP1A3—Parkinson's disease	0.000223	0.00154	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—SLC18A2—Parkinson's disease	0.00022	0.00152	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—NGF—Parkinson's disease	0.000218	0.00151	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—CP—Parkinson's disease	0.000214	0.00148	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—GSTM1—Parkinson's disease	0.000213	0.00147	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—HGF—Parkinson's disease	0.000213	0.00147	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—HSPA8—Parkinson's disease	0.000208	0.00144	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—Parkinson's disease	0.000208	0.00144	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—GSTP1—Parkinson's disease	0.000205	0.00142	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—HMOX1—Parkinson's disease	0.000202	0.0014	CbGpPWpGaD
Sibutramine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—Parkinson's disease	0.0002	0.00139	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—DLG4—Parkinson's disease	0.000196	0.00135	CbGpPWpGaD
Sibutramine—CYP3A4—Tryptophan metabolism—CYP2E1—Parkinson's disease	0.000192	0.00133	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—GRIN2B—Parkinson's disease	0.000191	0.00132	CbGpPWpGaD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—Parkinson's disease	0.000191	0.00132	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—HGF—Parkinson's disease	0.000189	0.0013	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—GSTM1—Parkinson's disease	0.000189	0.0013	CbGpPWpGaD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—MAOB—Parkinson's disease	0.000185	0.00128	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—CHRNA4—Parkinson's disease	0.000174	0.00121	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—Parkinson's disease	0.000172	0.00119	CbGpPWpGaD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2D6—Parkinson's disease	0.00017	0.00117	CbGpPWpGaD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP2D6—Parkinson's disease	0.000167	0.00116	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—COMT—Parkinson's disease	0.00016	0.00111	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—HSPA8—Parkinson's disease	0.00016	0.0011	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—MAOA—Parkinson's disease	0.000159	0.0011	CbGpPWpGaD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—Parkinson's disease	0.000155	0.00107	CbGpPWpGaD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—Parkinson's disease	0.000153	0.00106	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—DLG4—Parkinson's disease	0.00015	0.00104	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—GRIN2B—Parkinson's disease	0.000146	0.00101	CbGpPWpGaD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2D6—Parkinson's disease	0.000138	0.000951	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC18A2—Parkinson's disease	0.000134	0.000924	CbGpPWpGaD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—Parkinson's disease	0.000126	0.00087	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—IL1B—Parkinson's disease	0.000123	0.000851	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—CP—Parkinson's disease	0.000123	0.000851	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CASP3—Parkinson's disease	0.000123	0.000849	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—COMT—Parkinson's disease	0.000123	0.000849	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—MAOA—Parkinson's disease	0.000122	0.000843	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC18A2—Parkinson's disease	0.000118	0.000819	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—GSTA4—Parkinson's disease	0.00011	0.000763	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—CP—Parkinson's disease	0.000109	0.000754	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—GSTA4—Parkinson's disease	0.000109	0.000752	CbGpPWpGaD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—Parkinson's disease	0.000103	0.000716	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—MAOB—Parkinson's disease	9.83e-05	0.00068	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—MAPK8—Parkinson's disease	9.22e-05	0.000637	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—TNF—Parkinson's disease	8.93e-05	0.000618	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	8.76e-05	0.000606	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—CYCS—Parkinson's disease	8.41e-05	0.000582	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—CYCS—Parkinson's disease	7.45e-05	0.000516	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	7.31e-05	0.000506	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—CYP2D6—Parkinson's disease	7.31e-05	0.000505	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—IL6—Parkinson's disease	7.21e-05	0.000499	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP2D6—Parkinson's disease	7.2e-05	0.000498	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	7.02e-05	0.000486	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—CYP2E1—Parkinson's disease	6.68e-05	0.000462	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP2E1—Parkinson's disease	6.59e-05	0.000456	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	6.48e-05	0.000448	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	6.22e-05	0.00043	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—IL6—Parkinson's disease	5.88e-05	0.000407	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—COMT—Parkinson's disease	5.54e-05	0.000383	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—GSTP1—Parkinson's disease	5.51e-05	0.000381	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—MAOA—Parkinson's disease	5.5e-05	0.00038	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—COMT—Parkinson's disease	5.46e-05	0.000378	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—GSTP1—Parkinson's disease	5.43e-05	0.000376	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—GSTM1—Parkinson's disease	5.06e-05	0.00035	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—GSTM1—Parkinson's disease	4.99e-05	0.000345	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ND3—Parkinson's disease	3.59e-05	0.000248	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—MCCC1—Parkinson's disease	3.59e-05	0.000248	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—TALDO1—Parkinson's disease	3.38e-05	0.000233	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—OMD—Parkinson's disease	3.38e-05	0.000233	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	3.2e-05	0.000221	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GCH1—Parkinson's disease	3.05e-05	0.000211	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GBA—Parkinson's disease	2.72e-05	0.000188	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—FBP1—Parkinson's disease	2.72e-05	0.000188	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—DBH—Parkinson's disease	2.72e-05	0.000188	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—DDC—Parkinson's disease	2e-05	0.000138	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTA4—Parkinson's disease	1.89e-05	0.00013	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	1.7e-05	0.000117	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—MAOB—Parkinson's disease	1.68e-05	0.000116	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	1.25e-05	8.64e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CTGF—Parkinson's disease	1.23e-05	8.48e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	1.14e-05	7.9e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NQO1—Parkinson's disease	1.13e-05	7.81e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—TH—Parkinson's disease	1.11e-05	7.7e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYCS—Parkinson's disease	1.07e-05	7.39e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—COMT—Parkinson's disease	9.47e-06	6.55e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTP1—Parkinson's disease	9.42e-06	6.52e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—MAOA—Parkinson's disease	9.4e-06	6.5e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—HMOX1—Parkinson's disease	9.29e-06	6.43e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ABCB1—Parkinson's disease	8.92e-06	6.17e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTM1—Parkinson's disease	8.66e-06	5.99e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GPX1—Parkinson's disease	8.29e-06	5.74e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—MTHFR—Parkinson's disease	7.65e-06	5.29e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—APOE—Parkinson's disease	7.12e-06	4.93e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—INS—Parkinson's disease	6.09e-06	4.21e-05	CbGpPWpGaD
